Fig. 2: PLOD3 was the key regulator for Trastuzumab resistance in gastric cancer in vivo.
From: PLOD3 contributes to HER-2 therapy resistance in gastric cancer through FoxO3/Survivin pathway
A In vivo evaluation of the effect of PLOD3 on tumor proliferation. B Examined cell proliferation and apoptosis of indicated tumor tissues derived from in vivo models by western blot.
